Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAPGEF3 | O95398 | 1/20 | 0.56 |
| ▸ | PRMT5 | O14744 | 12/20 | 0.49 |
| ▸ | WDR77 | Q9BQA1 | 10/20 | 0.49 |
| ▸ | ADK | P55263 | 1/20 | 0.48 |
| ▸ | STING1 | Q86WV6 | 5/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1595241 | 1.00 | RAPGEF3 (0.56) | RAPGEF3PRMT5WDR77ADKSTING1 | |
| SCHEMBL23351431 | 1.00 | RAPGEF3 (0.56) | RAPGEF3PRMT5WDR77ADKSTING1 | |
| SCHEMBL14111697 | 0.91 | RAPGEF3 (0.46) | RAPGEF3PRMT5WDR77ADKSTING1 | |
| SCHEMBL3292767 | 0.90 | PRMT5 (0.45) | RAPGEF3PRMT5WDR77 | |
| SCHEMBL14946346 | 0.84 | STING1 (0.56) | RAPGEF3STING1 | |
| SCHEMBL23813544 | 0.84 | STING1 (0.56) | RAPGEF3STING1 | |
| SCHEMBL9964279 | 0.84 | STING1 (0.56) | RAPGEF3STING1 | |
| SCHEMBL22983991 | 0.84 | STING1 (0.56) | RAPGEF3STING1 | |
| SCHEMBL6895355 | 0.84 | STING1 (0.56) | RAPGEF3STING1 | |
| SCHEMBL16271105 | 0.84 | STING1 (0.56) | RAPGEF3STING1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040014957-A1 | Oligonucleotides having modified nucleoside units | ISIS PHARMACEUTICALS, INC. | 2004-01-22 | — | — | US | disclosed |
| US-20040014108-A1 | Oligonucleotides having modified nucleoside units | ISIS PHARMACEUTICALS, INC. | 2004-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014108-A1 | Oligonucleotides having modified nucleoside units | RNASEH1, RNASE1, RNASEL | RAPGEF3 3095/4885PRMT5 2966/4885WDR77 1841/4885 |
| US-20040014957-A1 | Oligonucleotides having modified nucleoside units | RNASE1, RNASEH1, RNASEL | RAPGEF3 3188/4885PRMT5 3154/4885WDR77 1648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.